Compare COEP & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COEP | CXH |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 66.4M |
| IPO Year | N/A | N/A |
| Metric | COEP | CXH |
|---|---|---|
| Price | $11.98 | $8.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 36.8K | 24.7K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.87 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $7.34 |
| 52 Week High | $21.41 | $8.39 |
| Indicator | COEP | CXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 40.62 |
| Support Level | $10.65 | $7.89 |
| Resistance Level | $13.23 | $8.04 |
| Average True Range (ATR) | 0.88 | 0.10 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 78.01 | 32.50 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.